Clinical trials: SARS-COV2
COVID-19, Diabetes Mellitus
Incidence of Diabetes After a COVID-19 Infection
Prospective observational study of the POINTED consortium to evaluate whether new diagnoses of diabetes mellitus, occur significantly more frequently in the post-acute phase of a laboratory-confirmed SARS-CoV-2 infection than in…
- Trial name
- POINTED_Diab (NCT05524792)
- Testing
- no interventional study
- Where
- Germany
- Volunteers
- 157,134 people
- Sponsor
- InGef - Institute for Applied Health Research Berlin GmbH
SARS-CoV Infection, Respiratory Viral Infection
COVID-19 Testing Sample Acquisition Throughput and Efficiency
This QI project seeks to evaluate the relative test sample acquisition throughput, personal protective equipment utilization, and relative operational costs of provider-administered COVID-19 (SARS-CoV-2) nasal samples with and…
- Conditions
- SARS-CoV Infection, Respiratory Viral Infection, Personal Protective Equipment, Covid19
- Trial name
- HexapodBooth (NCT04532411)
- Testing
- Personal Protective Testing Booth
- Where
- United States
- Volunteers
- 28,948 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
COVID-19
Study to Evaluate the Effects of RO7496998 (AT-527) in Non-Hospitalized Adult and Adolescent Participants With Mild or Moderate COVID-19
This study will evaluate the efficacy, safety, antiviral activity, and pharmacokinetics of study drug RO7496998 (AT-527) compared to placebo in non-hospitalized adult and adolescent participants with mild to moderate coronavirus…
- Trial name
- MORNINGSKY (NCT04889040)
- Testing
- RO7496998
- Where
- 50 sites in Argentina, Belgium and 10 more
- Volunteers
- 216 people
- Sponsor
- Hoffmann-La Roche
COVID-19
Intranasal Heparin Treatment to Reduce Transmission Among Household Contacts of COVID 19 Positive Adults and Children
Coronavirus-induced disease 2019 (COVID-19) is an infection caused by a virus whose full name is severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
- Trial name
- INHERIT (NCT05204550)
- Testing
- unfractionated heparin, 0.9%sodium chloride
- Where
- Australia
- Volunteers
- 506 people
- Sponsor
- Murdoch Childrens Research Institute
Emergencies, Epidemic Disease
Impact of the Qatar 2022 FIFA World Cup on PED Use and Misuse Patterns
A retrospective cohort study to explore the impact of the FIFA World Cup 2022 Qatar on paediatric emergency department attendance at two tertiary centres during unprecedent winter viral epidemics.
- Conditions
- Emergencies, Epidemic Disease, Pediatric ALL, Electronic Medical Record
- Trial name
- NCT05818215
- Testing
- NO intervention
- Where
- Switzerland
- Volunteers
- 18,000 people
- Sponsor
- Pediatric Clinical Research Platform
Telehealth
A Comparison of 3D and 2D Telemedicine During Covid 19
It is critical to establish an effective form of telemedicine during the Covid 19 pandemic, that will allow safe social distancing of clinicians and patients.
- Trial name
- NCT04359225
- Testing
- 3D Telemedicine, 2D Telemedicine
- Where
- United Kingdom
- Volunteers
- 80 people
- Sponsor
- NHS Greater Glasgow and Clyde
COVID, Neurologic Manifestations
Neurologic Manifestations of COVID 19 in Children
The purpose of this study is to perform a secondary analysis of pre-existing de-identified limited datasets obtained from sites participating in Tier 1 (STUDY20040154: Neurologic Manifestations of COVID 19 in Children) and Tier 2…
- Trial name
- NCT04379089
- Testing
- Observational study only
- Where
- United States
- Volunteers
- 3,568 people
- Sponsor
- University of Pittsburgh
Cystic Fibrosis
COVID-19 Antibody Responses In Cystic Fibrosis
Coronavirus disease 2019 (COVID-19) which is caused by the virus SARS-CoV-2 has resulted in an ongoing global pandemic. It is unclear whether the relatively low number of reported cases of COVID-19 in people with CF (pwCF) is due…
- Trial name
- CAR-CF (NCT05074680)
- Testing
- Blood sampling
- Where
- 2 sites in Switzerland
- Volunteers
- 5 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
COVID-19 Pandemic
A PhaseⅡ Study to Evaluate the Safety & Immunogenicity of SARS-CoV-2 Alpha/Beta/Delta/Omicron Variants COVID-19 Vaccine
This study is a randomized, double-blind, placebo-controlled Phase II clinical trial to evaluate the safety and immunogenicity of SCTV01E in population of different ages who have been vaccinated against COVID-19.
- Trial name
- SCTV01E (NCT05652543)
- Testing
- SCTV01E
- Where
- 4 sites in China
- Volunteers
- 518 people, healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
SARS-CoV-2 Infection, COVID-19
A Study to Learn About New COVD-19 RNA Vaccine Candidates for New Variants in Healthy Individuals
The purpose of this clinical protocol is to learn about the safety, tolerability, and immunogenicity of new BNT162b2 RNA-based vaccine candidates targeting new variants of SARS-CoV-2 in healthy people.
- Trial name
- NCT05997290
- Testing
- BNT162b2 (Omi XBB.1.5), BNT162b2 (Omi JN.1), BNT162b2 (Omi KP.2)
- Where
- 37 sites in United States
- Volunteers
- 1,051 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
Mental Health Wellness 1, COVID
Telepsychoeducation for the Prevention of Emotional Distress in Professionals and Students From Essential Services in the Context of COVID-19
A pragmatic superiority randomized controlled trial comparing Telepsychoeducation plus personalized videos vs. Telepsychoeducation without personalized videos for the prevention of future emotional distress in professionals and…
- Conditions
- Mental Health Wellness 1, COVID, Emotional Distress, Depressive Symptoms
- Trial name
- NCT04632082
- Testing
- Telepsychoeducation with personalized videos, Telepsychoeducation without personalized videos
- Where
- Brazil
- Volunteers
- 2,200 people
- Sponsor
- Hospital de Clinicas de Porto Alegre
Sars-CoV2, Breastmilk
Is COVID-19 Transmitted Through Human Milk? Implications for Breastfeeding and Human Milk Banking-Study 1b
The Canadian Paediatric Society recommends breastfeeding during COVID-19 infection. Human milk is the best form of infant nutrition providing significant protection against many illnesses for term and preterm infants.
- Trial name
- NCT04453982
- Testing
- Human milk donors
- Where
- Canada
- Volunteers
- 384 people, healthy volunteers welcome
- Sponsor
- Deborah O'Connor
Coagulation Disorder
Evaluation of Coagulopathy in Critically Ill COVID-19 Patients.
Novel coronavirus disease 19 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), this pneumonia was first emerged in December 2019 in Wuhan, China and rapidly spread around the world .
- Trial name
- NCT04479280
- Testing
- Sonclot Coagulation and platelet function Analyzer SCP1, Sienco, USA
- Where
- Egypt
- Volunteers
- 70 people
- Sponsor
- Assiut University
Long COVID, Long Covid19
Stellate Ganglion Block to Treat Long COVID 19 Case Series
An assessment of the effectiveness of Stellate Ganglion Block in alleviating symptoms of Long COVID-19.
- Conditions
- Long COVID, Long Covid19, Post-COVID-19 Syndrome, Post Acute COVID-19 Syndrome
- Trial name
- NCT05812209
- Testing
- Stellate Ganglion Block
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Metamorphosis LTD
Prevention of Infectious Disease Caused by SARS-CoV-2
VAXZEVRIA Japan Post-Marketing Surveillance (PMS) for the Long-term Safety of VAXZEVRIA
This survey will be conducted for the subjects who participate in the priority survey (cohort survey) conducted by the Scientific Research Group of the Ministry of Health, Labour and Welfare at the initial stage of administration…
- Trial name
- NCT05135455
- Where
- 6 sites in Japan
- Volunteers
- 467 people
- Sponsor
- AstraZeneca
Covid19
COVID-19 Vaccine Text Outreach
This project aims to evaluate different approaches to increase COVID-19 vaccine uptake among at-risk patients at Penn Medicine in an equitable and systematic manner through a centralized outreach program.
- Trial name
- NCT04834726
- Testing
- Opt-In (Call-Back), Opt-in (In-Bound), Standard Message
- Where
- United States
- Volunteers
- 19,554 people
- Sponsor
- University of Pennsylvania
Covid19
PCR Cycle Threshold Values and COVID-19 Outcomes
This is a retrospective observational study. The study will use high quality, reliable data that has already been collected for the ISARIC 4C COVID-19 study in order to analyse the relation between predictor variables (laboratory…
- Trial name
- NCT04651413
- Testing
- PCR Value
- Where
- United Kingdom
- Volunteers
- 934 people, healthy volunteers welcome
- Sponsor
- University Hospitals of North Midlands NHS Trust
Covid19
TOCILIZUMAB - An Option for Patients With COVID-19 Associated Cytokine Release Syndrome; A Single Center Experience
Investigators conducted this study to see the effectiveness of Tocilizumab in COVID-19 participants who were in cytokine release syndrome and there was also a control group who received steroids(RECOVERY TRIAL wasn't published or…
- Trial name
- NCT04730323
- Testing
- Tocilizumab
- Where
- Pakistan
- Volunteers
- 93 people
- Sponsor
- FMH College of Medicine and Dentistry
Paediatric Inflammatory Multisystem Syndrome-Temporally Associated With SARS-CoV-2 (PIMS-TS)
Randomised Evaluation of COVID-19 Therapy (RECOVERY) in Children With PIMS-TS in Switzerland (SWISSPED-RECOVERY)
The study is to provide reliable estimates of the effect of study treatment on hospital length of stay through to 28 days after randomisation.
- Trial name
- NCT04826588
- Testing
- Methylprednisolone sodium succinate 10 mg/kg intravenously, Human normal immunoglobulin (IVIg)
- Where
- 10 sites in Switzerland
- Volunteers
- 76 people
- Sponsor
- University Children's Hospital Basel
Severe Acute Respiratory Syndrome Coronavirus 2
Treatment Of CORONAVIRUS DISEASE 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP)
This treatment protocol is designed to provide convalescent plasma as a therapeutic option for patients diagnosed with and hospitalized for COVID-19 with symptoms ranging from mild to life-threatening.
- Trial name
- NCT04360486
- Testing
- Anti-Sars-CoV-2 Convalescent Plasma
- Where
- 38 sites in United States, Afghanistan and 6 more
- Sponsor
- U.S. Army Medical Research and Development Command